HeyJaredGSK
GSK’s website functions as a corporate news and information hub for one of the world’s largest biopharmaceutical companies, rather than as an independent news outlet.
- Indexed articles, last 90 days
- 22
- Latest publication
- Jul 30, 2026
- Audience
- Top 500K sites
- Earliest in this view
- Jul 9, 2026
Latest articles
Flagship R&D centre in Cambridge, UK | GSK (opens the original)
Read excerpt
We will be establishing a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D. GSK's new 300,000 sq ft R&D centre on the Cambridge Biomedical Campus, will be home to more than 1,000 GSK scientists. Featuring state-of-the-art, tech-enabled labs and infrastructure, it will provide direct access to a world-class ecosystem of biomedical research, patien
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 (opens the original)
Read excerpt
Superiority data from LATA together with OPERA findings add to the clinical and real-world evidence base for long-acting injectable Cabenuva
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK | GSK (opens the original)
Read excerpt
Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia Catalyst to fuel collaboration and accelerate GSK R&D and medicine development £400 million investment in UK life sciences GSK plc (LSE/NYSE: GSK) today announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot site, on the Cambridge Biomedical Campus in the heart of the UK’s
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK (opens the original)
Read excerpt
Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026 (opens the original)
Read excerpt
Q2 results 2026
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.